The relapsed or refractory diffuse large B-cell lymphoma market refers to treatment options available for patients who experience failure of initial treatment or relapse after achieving remission following first-line therapy. Diffuse large B-cell lymphoma is an aggressive type of non-Hodgkin lymphoma. Treatment for relapsed or refractory diffuse large B-cell lymphoma relies on CD20 monoclonal antibodies along with chemotherapy drugs. However, with the development of new targeted therapies and immunotherapies over the past few years, treatment landscapes are evolving to include CAR-T cell therapies and bispecific antibodies.

The Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market is estimated to be valued at US$ 1777.75 Bn in 2024 and is expected to exhibit a CAGR of 16% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the relapsed or refractory diffuse large B-cell lymphoma market are Sharp Corp., LG, Samsung, Hitachi, and Panasonic. With approvals of new CAR-T cell therapies and bispecific antibodies, treatment landscapes are changing rapidly. Growing demand for effective targeted therapies to treat relapse or refractory disease is driving research and development in this segment. Several pharmaceutical companies are expanding globally with clinical trials and partnerships to commercialize new immunotherapies for relapsed or refractory diffuse large B-cell lymphoma.

Market key Trends

One of the key trends in the Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Market Trends is the approval and launch of novel CAR T-cell therapies and bispecific antibodies. These novel targeted therapies have demonstrated high response rates compared to chemotherapy in clinical trials. Drugs like axicabtagene ciloleucel (YESCARTA), tisagenlecleucel (KYMRIAH), and loncastuximab tesirine (ZYNLONTA) have established role in relapsed or refractory diffuse large B-cell lymphoma treatment algorithms. Their commercialization will significantly boost the market growth over the forecast period from 2024-2030.

Porter’s Analysis

Threat of new entrants: High capital investment and requirement of strong manufacturing and distribution infrastructure limits potential new entrants.

Bargaining power of buyers: Buyers including hospitals and treatment centers have moderate bargaining power due to availability of alternative treatments.

Bargaining power of suppliers: Suppliers have low to moderate bargaining power as there exist many large established suppliers in the market.

Threat of new substitutes: Threat of new substitutes is low as there are limited treatment options available for relapsed or refractory diffuse large B-cell lymphoma currently.

Geographical Regions

North America currently holds the largest share of the global relapsed or refractory diffuse large B-cell lymphoma market in terms of value owing to high awareness about lymphoma treatment and availability of advanced treatment options.

Asia Pacific is expected to witness the fastest growth during the forecast period driven by expanding healthcare infrastructure, rising healthcare spending, and increasing awareness about lymphoma treatment in major countries like China and India.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it.